Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Core Insights - Genmab A/S will present new research from its late-stage portfolio at the 2025 ASCO Annual Meeting from May 30 to June 3 in Chicago, Illinois [1] - The presentations will include results from a Phase 1/2 trial of rinatabart sesutecan (Rina-S) for recurrent/advanced endometrial cancer and long-term follow-up data from the EPCORE NHL-1 study of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma [2][8] Company Commitment - Genmab emphasizes its commitment to advancing antibody science for patients needing alternative treatment options, particularly for endometrial cancers with rising mortality rates [3] - The company is encouraged by Rina-S as a potential treatment option for endometrial cancer and continues to evaluate epcoritamab as a core therapy across B-cell malignancies in collaboration with AbbVie [3][15] Event Details - Genmab will host a virtual review of the Rina-S data presented at ASCO on June 2 at 4:00 PM CDT, with details available on their investor relations website [4] Abstracts and Presentations - Abstracts accepted for presentation at ASCO include key studies on Rina-S and epcoritamab, with specific presentation times outlined [5][7]